货号:A851897
同义名:
GW257406X; 1263W94
Maribavir是一种有效的野生型pUL97催化的组蛋白磷酸化抑制剂,IC50为3 nM。它对HCMV和Epstein-Barr病毒(EBV)具有强效的抗病毒活性。
规格 | 价格 | 会员价 | 库存 | 数量 | |||
---|---|---|---|---|---|---|---|
{[ item.pr_size ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]} | 现货 | 1周 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解
描述 | Maribavir effectively inhibits the autophosphorylation of both wild-type and major Ganciclovir (GCV) resistant UL97 mutants, with an average IC50 of 35 nM. The M460I mutation exhibits increased sensitivity to Maribavir, having an IC50 of 4.8 nM, while the Maribavir-resistant UL97 mutant L397R shows reduced kinase activity to about 10% of the wild type. Enzyme kinetics reveal Maribavir acts as a competitive inhibitor of ATP with a Ki of 10 nM[1]. Additionally, Maribavir suppresses viral replication dose-dependently with an IC50 of 0.12±0.01 μM in multicycle DNA hybridization assays, and strongly inhibits the pUL97 protein kinase at a 50% inhibition concentration of 3 nM[2]. |
体外研究 | Maribavir effectively inhibits the autophosphorylation of both wild-type and major Ganciclovir (GCV) resistant UL97 mutants, with an average IC50 of 35 nM. The M460I mutation exhibits increased sensitivity to Maribavir, having an IC50 of 4.8 nM, while the Maribavir-resistant UL97 mutant L397R shows reduced kinase activity to about 10% of the wild type. Enzyme kinetics reveal Maribavir acts as a competitive inhibitor of ATP with a Ki of 10 nM[1]. Additionally, Maribavir suppresses viral replication dose-dependently with an IC50 of 0.12±0.01 μM in multicycle DNA hybridization assays, and strongly inhibits the pUL97 protein kinase at a 50% inhibition concentration of 3 nM[2]. |
Concentration | Treated Time | Description | References | |
Akata cells | 20 µM | 24 hours | MBV inhibits phosphorylation of EBV early antigen EA-D | J Virol. 2009 Dec;83(23):12108-17. |
Akata cells | 20 µM | 24 hours | MBV almost completely inhibited the appearance of the 54-kDa and 52-kDa EA-D products and also reduced the level of 49-kDa EA-D | J Virol. 2009 Dec;83(23):12108-17. |
293 cells | 20 µM | 48 hours | MBV inhibits EBV transcription and replication by inhibiting BGLF4 protein kinase activity | J Virol. 2013 May;87(9):5311-5. |
Human foreskin fibroblasts (HFF) | 10 µM | 5 to 6 days | To evaluate the effect of MBV on GCV antiviral activity, results showed MBV increased GCV EC50 by 13-fold | Antimicrob Agents Chemother. 2006 Oct;50(10):3470-2. |
Human embryonic lung (HEL) fibroblasts | 0.32 µM | 5 to 6 days | To evaluate the effect of MBV on GCV antiviral activity, results showed MBV increased GCV EC50 by ninefold | Antimicrob Agents Chemother. 2006 Oct;50(10):3470-2. |
Human foreskin fibroblast (HFF) | 0.5-25 µM | 5-20 passages | Selection of UL97 and UL27 mutations, discovery of new UL97 mutation L337M and UL27 mutations D534Y, R448P | Antiviral Res. 2012 Aug;95(2):88-92. |
ARPEp cells | 48.0 µM | 6 days | Evaluate the inhibitory effect of Maribavir on L397R mutant CMV, EC50 was 48.0 μM | Antiviral Res. 2024 Feb;222:105792. |
ARPEp cells | 0.118 µM | 6 days | Evaluate the inhibitory effect of Maribavir on wild-type CMV, EC50 was 0.118 μM | Antiviral Res. 2024 Feb;222:105792. |
MRC-5 fibroblasts | 40 µM | 72 hours | Evaluate the inhibitory effect of MBV on hCMV DNA synthesis, results showed MBV alone reduced viral DNA levels by an average of 95% | Antiviral Res. 2013 Nov;100(2):321-7. |
U373 cells | 40 µM | 72 hours | Evaluate the inhibitory effect of MBV on hCMV DNA synthesis, results showed MBV alone reduced viral DNA levels by an average of 40% | Antiviral Res. 2013 Nov;100(2):321-7. |
Human embryonic lung fibroblasts | 0.1-10 µM | weekly passage | To evaluate the antiviral activity of Maribavir against CMV and the emergence of resistance mutations | Antimicrob Agents Chemother. 2009 Jan;53(1):81-5. |
NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
NCT00002373 | Cytomegalovirus Infections ... 展开 >> HIV Infections 收起 << | Phase 1 | Completed | - | United States, California ... 展开 >> Univ of California/ San Francisco / Dept of Medicine San Francisco, California, United States, 94110 Dr Jacob Lalezari San Francisco, California, United States, 94115 收起 << |
NCT00411645 | Cytomegalovirus Infections | Phase 3 | Completed | - | - |
NCT00497796 | Cytomegalovirus Infections | Phase 3 | Completed | - | - |
计算器 | ||||
存储液制备 | ![]() |
1mg | 5mg | 10mg |
1 mM 5 mM 10 mM |
2.66mL 0.53mL 0.27mL |
13.29mL 2.66mL 1.33mL |
26.58mL 5.32mL 2.66mL |
CAS号 | 176161-24-3 |
分子式 | C15H19Cl2N3O4 |
分子量 | 376.24 |
SMILES Code | CC(C)NC1=NC2=C(C=C(Cl)C(Cl)=C2)N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O |
MDL No. | MFCD00945570 |
别名 | GW257406X; 1263W94; VP-41263; SHP-620; GW-1263; BW1263W94 |
运输 | 蓝冰 |
存储条件 |
In solvent -20°C: 3-6个月 -80°C: 12个月 Pure form Keep in dark place, sealed in dry, 2-8°C |
溶解方案 |
DMSO: 190 mg/mL(505 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO 以下溶解方案都请先按照体外实验的方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议现用现配,当天使用; 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶
|